Your shopping cart is currently empty

SB-612111 is a novel and potent human opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (Ki = 0.33 nM). It exhibits selectivity for μ-, κ-, and δ-receptors with Ki values of 57.6 nM, 160.5 nM, and 2109 nM, respectively. SB-612111 effectively antagonizes the pronociceptive action of Nociceptin in an acute pain model[1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $3,560 | 10-14 weeks | 10-14 weeks | |
| 50 mg | $4,990 | 10-14 weeks | 10-14 weeks | |
| 100 mg | $6,990 | 10-14 weeks | 10-14 weeks |
| Description | SB-612111 is a novel and potent human opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (Ki = 0.33 nM). It exhibits selectivity for μ-, κ-, and δ-receptors with Ki values of 57.6 nM, 160.5 nM, and 2109 nM, respectively. SB-612111 effectively antagonizes the pronociceptive action of Nociceptin in an acute pain model[1]. |
| Targets&IC50 | δ opioid receptor:2109 nM (Ki), κ opioid receptor:160.5 nM (Ki), ORL1 (human):0.33 nM (Ki), μ opioid receptor:57.6 nM (Ki) |
| Molecular Weight | 418.40 |
| Formula | C24H29Cl2NO |
| Cas No. | 371980-98-2 |
| Smiles | ClC1=C(C2CCN(C[C@@H]3C[C@H](O)C=4C(CC3)=C(C)C=CC4)CC2)C(Cl)=CC=C1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: Soluble |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.